Clotrimazole/Betamethasone

DEA Class; Rx

Common Brand Names; Lotrisone

Topical product containing betamethasone, a high potency corticosteroid, and clotrimazole, an imidazole antifungal
Indicated to treat cutaneous tinea infections
Can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression

Documented hypersensitivity

Dry skin (2%)

Paresthesia (2%)

Local burning (2%)

Edema

Rash

Skin atrophy

Secondary infection

Skin ulceration

Acneiform eruption

Bruising

Folliculitis

Striae

Clotrimazole

• Erythema
• Stinging
• Blistering
• Peeling
• Edema
• Pruritus
• Urticaria
• General skin irritation
• Blurred vision, cataracts, glaucoma, increased intraocular pressure

Betamethasone

• Burning
• Itching
• Irritation
• Dryness
• Folliculitis
• Hypertrichosis
• Acneiform eruptions
• Hypopigmentation
• Perioral dermatitis
• Allergic contact dermatitis
• Skin maceration
• Skin atrophy
• Striae
• Miliaria
• HPA suppression (with higher potency used >2 wk)

Do not use with occlusive dressing; systemic absorptioin of topical corticosteroids may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal axis

Prolonged treatment with corticosteroids associated with development of Kaposi sarcoma

Occlusive dressings, prolonged use, application to denuded skin or to large surface aread may increase absorption and result in hyperglycemia, glycosuria, or Cushing syndrome

Not for use in the treatment of diaper dermatitis in any age group; significant adverse reactions associated with corticosteroids reported

Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma; cataracts and glaucoma reported in postmarketing experience with use of topical corticosteroid products, including topical betamethasone products; avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation

There are no available data on topical betamethasone dipropionate or clotrimazole use in pregnant women to identify drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; observational studies suggest an increased risk of low birthweight infants with use of potent or very potent topical corticosteroid during pregnancy

Advise a woman to apply drug to smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women not to apply drug directly to nipple and areola to avoid direct infant exposure

No maximum dosage information is available.

No maximum dosage information is available.

>= 17 years: No maximum dosage information is available.
< 17 years: Use not recommended.

Use not recommended.